头颈癌自适应与剂量重分布放疗对比常规放疗:ARTFORCE III期试验生活质量结果
ARTFORCE III期试验比较FDG/PET引导剂量重分布联合计划性治疗自适应(rRT)与常规放疗(cRT)在头颈癌患者中的患者报告生活质量(QoL)。221例中142例(64%)完成至少一次QoL问卷并纳入分析,采用线性混合效应模型纵向分析。两组QoL总体相当,仅cRT组1年黏稠唾液主诉显著增加、2年整体健康状况显著下降;QoL主要受基线QoL值影响,治疗后初期下降后在随访中改善。
要点
- rRT与cRT的QoL总体相当,仅cRT组1年黏稠唾液主诉显著增加、2年整体健康状况显著下降。
- 多数模型中QoL与基线QoL值显著相关,治疗后初期下降后随访中改善。
- 剂量重分布联合计划性治疗自适应是提高肿瘤亚区剂量的安全策略。
核心结论
- 与常规放疗相比,FDG/PET引导剂量重分布联合计划性治疗自适应未导致QoL总体变差,仅cRT组在1年黏稠唾液主诉和2年整体健康状况方面显著更差。
- 该剂量重分布策略是提高肿瘤亚区剂量的安全策略,与试验主要结果一致。
研究设计与样本
- ARTFORCE为III期试验(NCT01504815),比较FDG/PET引导剂量重分布联合计划性治疗自适应(rRT)与常规放疗(cRT)在头颈癌患者中的患者报告QoL。
- QoL在基线、放疗后即刻及6个月、1年、2年、5年随访时采用EORTC QLQ C30、EORTC QLQ HN35和EQ-5D-5L评估。
- 221例患者中142例(64%)完成至少一次QoL问卷并纳入分析,采用线性混合效应模型(LMM)进行纵向分析。
主要发现
- 两组QoL总体相当,但cRT组较rRT组在1年时黏稠唾液主诉显著增加、2年时整体健康状况显著下降。
- 多数LMM中患者QoL与基线QoL值显著相关,治疗后初期QoL下降后在随访中改善。
- 总体QoL在随访6个月时改善。
临床怎么用
- 该剂量重分布联合计划性治疗自适应策略可安全用于提高头颈癌肿瘤亚区剂量,QoL总体与常规放疗相当。
- 临床解读QoL变化时应考虑患者基线QoL值,因其对多数QoL结局有显著影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study compared patient-reported quality of life (QoL) between patients with head and neck cancer treated with either FDG/PET-guided dose redistribution with scheduled treatment adaptation (rRT) or conventional radiotherapy (cRT). METHODS: QoL outcomes were assessed at baseline, directly after radiotherapy and at 6-month, 1-, 2-, and 5-year follow up using the EORTC QLQ C30, EORTC QLQ HN35 and EQ-5D-5L. Linear mixed-effects models (LMMs) were used for longitudinal analysis including fixed effects for baseline QoL scores, trial arm, time, an interaction term between trial arm and time and random effects for patients. RESULTS: 142 out of 221 patients (64 %) filled out at least one QoL questionnaire and were included for analysis. QoL was overall comparable between trial arms, with exception of a significant increase in sticky saliva complaints at 1 year and decreased global health status at 2 years in cRT compared to rRT. In the majority of the other LMMs, patients' QoL was significantly associated with their baseline QoL values and initial QoL deterioration observed after treatment was followed by improvement throughout follow up. CONCLUSIONS: In line with the primary results of the trial (ARTFORCE, NCT01504815), dose redistribution combined with scheduled treatment adaptation showed comparable QoL outcome to conventional radiotherapy. Overall, QoL was mostly determined by patients' individual baseline QoL and improved at 6 months of follow up. These results confirm that this dose redistribution strategy is a safe strategy to increase dose to tumor subregions.
引用
- de Leeuw ALMP, Hoebers FJP, Giralt J, et al. Comparing adaptive and dose redistributed radiotherapy to conventional radiotherapy in head and neck cancer - Quality of life results from the phase III ARTFORCE trial. Radiother Oncol. 2025. PMID: 40651596. doi:10.1016/j.radonc.2025.111044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。